<DOC>
	<DOCNO>NCT00337701</DOCNO>
	<brief_summary>This study evaluate sign symptom associate Fuzeon injection ( 90mg sc ) use B2000 needle-free injection device , HIV-1 positive patient experience Fuzeon treatment , difficulty tolerate long-term ( &gt; 4 week ) administration Fuzeon standard needle syringe . Patients randomize B2000 device standard needle syringe 4 week ; patient use B2000 device next 4 week . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>BOSS Study : A Study Fuzeon Using Needle-Free Biojector 2000 Patients With HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>adult patient &gt; =16 year age ; current former Fuzeon user may benefit needlefree administration Fuzeon ; naive use B2000 device ; positive test result human immunodeficiency virus infection . patient naive Fuzeon ; inability selfinject Fuzeon , reliable caregiver administer injection ; evidence active , untreated , opportunistic infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>